| Literature DB >> 35432241 |
Carla Hernández-Cabanyero1, Eva Sanjuán1, Felipe E Reyes-López2,3, Eva Vallejos-Vidal2,4, Lluis Tort3, Carmen Amaro1.
Abstract
Vibrio vulnificus is a marine zoonotic pathogen associated with fish farms that is considered a biomarker of climate change. Zoonotic strains trigger a rapid death of their susceptible hosts (fish or humans) by septicemia that has been linked to a cytokine storm in mice. Therefore, we hypothesize that V. vulnificus also causes fish death by triggering a cytokine storm in which red blood cells (RBCs), as nucleated cells in fish, could play an active role. To do it, we used the eel immersion infection model and then analyzed the transcriptome in RBCs, white BCs, and whole blood using an eel-specific microarray platform. Our results demonstrate that V. vulnificus triggers an acute but atypical inflammatory response that occurs in two main phases. The early phase (3 h post-infection [hpi]) is characterized by the upregulation of several genes for proinflammatory cytokines related to the mucosal immune response (il17a/f1 and il20) along with genes for antiviral cytokines (il12β) and antiviral factors (ifna and ifnc). In contrast, the late phase (12 hpi) is based on the upregulation of genes for typical inflammatory cytokines (il1β), endothelial destruction (mmp9 and hyal2), and, interestingly, genes related to an RNA-based immune response (sidt1). Functional assays revealed significant proteolytic and hemolytic activity in serum at 12 hpi that would explain the hemorrhages characteristic of this septicemia in fish. As expected, we found evidence that RBCs are transcriptionally active and contribute to this atypical immune response, especially in the short term. Based on a selected set of marker genes, we propose here an in vivo RT-qPCR assay that allows detection of early sepsis caused by V. vulnificus. Finally, we develop a model of sepsis that could serve as a basis for understanding sepsis caused by V. vulnificus not only in fish but also in humans.Entities:
Keywords: European eel; Vibrio vulnificus; blood; erythrocytes; host-pathogen relationship; immune response; zoonotic pathogen
Year: 2022 PMID: 35432241 PMCID: PMC9011161 DOI: 10.3389/fmicb.2022.852677
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 6.064
Microarray validation by RT-qPCR.
| Gene name | Gene acronym | Sample | FC | |
|---|---|---|---|---|
| Array | RT-qPCR | |||
| Beta-catenin-like protein 1 |
| B 3 vs. 0 hpi | 1.52 (=) | 1.87 (=) |
| Interleukin 1beta |
| B 12 vs. 0 hpi | 17.16 (++) | 23.44 (++) |
| Interleukin 10 receptor subunit beta |
| RBCs 3 vs. 0 hpi | 4.94 (+) | 5.24 (+) |
| Beta-catenin-like protein 1 |
| RBCs 12 vs. 0 hpi | −1.90 (=) | −1.03 (=) |
| p53 |
| WBCs 3 vs. 0 hpi | 6.76 (+) | 7.77 (+) |
| Interleukin 6 receptor subunit beta precursor |
| WBCs 12 vs. 0 hpi | 6.83 (=) | 4.87 (+) |
Comparison of fold change (FC) values obtained by microarray and RT-qPCR. In case of RT-qPCR, results were obtained using act as the reference gene and the fold induction (2 Supplementary Table S1. FC value represents the mean obtained from 3 independent biological samples.
FC: fold change values qualitative classification: =, −2 < X < 2; +, 2 ≤ X < 10; ++, 10 ≤ X < 25; ND, non-detected as differentially expressed.
Figure 1Magnitude of the eel immune response against V. vulnificus represented as the number of differentially expressed genes (DEGs) in blood (B), red blood cells (RBCs) and white blood cells (WBCs) samples. Bars represent total DEGs (sum of upregulated [red] and downregulated [green] DEGs) of each sampling point (3 hpi; 12 hpi) against time zero (0 hpi) of each type of sample. The numbers of up/downregulated DEGs are indicated on the top of each bar.
Eel blood transcriptome after V. vulnificus infection.
| Gene | FC | |||||
|---|---|---|---|---|---|---|
| B | RBCs | WBCs | ||||
| 3 hpi | 12 hpi | 3 hpi | 12 hpi | 3 hpi | 12 hpi | |
|
| ||||||
|
| ||||||
|
| – | 4.3 | – | – | – | – |
|
| – | −2.6 | – | – | – | – |
|
| – | – | 4.2 | – | 9.6 | – |
|
| – | – | 3.4 | – | 3.7 | – |
|
| – | – | 3.1 | – | 4.9 | – |
|
| – | – | 2.2 | 1.8 | – | – |
|
| – | – | – | – | 4.1 | – |
|
| – | – | – | – | 3.0 | – |
|
| – | – | – | – | 2.2 | – |
|
| – | – | – | – | −5.5 | – |
|
| ||||||
|
| – | 2.7 | 3–1.7 | 1.5 | – | – |
|
| – | – | 4.8–2 | 84.4 | 5.3–3.2 | 30.6 |
| AP-1 complex subunit sigma 3 | – | – | – | −2.0 | 3.8 | – |
| AP-1 complex subunit gamma 1 | – | – | – | – | 2.1 | – |
|
| ||||||
| Cathepsin L | – | 3.6 | – | – | 5.6 | – |
| Cathepsin S precursor | – | 2.9 | 1.8 | – | – | – |
| Cathepsin B | – | – | 2.5 | 5.3 | – | – |
|
| ||||||
|
| ||||||
| Transferrin | – | 2.7 | 2.5–2.1 | 1.8 | – | – |
| Transferrin receptor ( | – | 2.4 | – | – | – | – |
| Aminolevulinic acid | – | 2.0 | – | – | – | 2.1 |
| Hemoglobin subunit | – | – | – | 3.7 | – | – |
| Ferritin | – | – | – | 2.8–2.1 | – | – |
| Hepcidin | – | – | – | – | 10.2 | – |
|
| ||||||
| C5a receptor | – | 14.1 | – | – | – | – |
| Complement factor Bf-2 | – | 6.5–5.3 | – | – | – | – |
| Complement factor B/C2 | – | 5.9 | – | – | 2.4 | – |
| Complement factor B | – | 4.6 | – | – | – | – |
| C3a receptor 1 | – | – | 6.5 | – | 7.5 | – |
| C3c | – | – | 4.2 | – | 4.2 | – |
| C7-1 | – | – | 4.1 | – | 3.3 | – |
| C4BPB | – | – | 4.1 | 3.0 | 7.7 | – |
| C3 | – | – | 3.9 | – | 7.4 | – |
| C3-H2 | – | – | 3.6 | – | 4.2 | – |
| C3-H1 | – | – | 3.5 | – | 2.9 | – |
| C3-S | – | – | 3.1 | 1.9 | 5.6–2.6 | 1.9 |
| factor D precursor | – | – | 2.8 | – | – | – |
| C4-2 | – | – | 2.2 | – | 2.1 | 2.7 |
| C5 | – | – | – | – | 12.8 | – |
| C5-2 | – | – | – | – | 6.1 | – |
| C4 | – | – | – | – | 4.1 | – |
| C4b | – | – | – | – | 4.0 | – |
| C3-3 | – | – | – | – | 3.6 | – |
| C1R/C1S subunit of Ca2 + −dependent | – | – | – | – | 3.4–2.9 | – |
| C7 | – | – | – | – | 3.0 | – |
| Complement factor I | – | – | – | – | 2.3 | – |
| C3 precursor | – | – | – | – | 2.2 | – |
| C1q, B chain | – | – | – | – | – | 7.7 |
|
| ||||||
| Nephrosin ( | 10.1–6.3 | 150.6–99 | – | – | – | – |
| Lpb/Bpi | 4.5–3.3 | 41.7–25 | – | – | – | – |
| Nitric oxide synthase | – | – | – | – | 3.4 | – |
|
| ||||||
| Mannose-6-phosphate receptor-binding | – | 14.0 | – | – | – | – |
| C-type lectin receptor | – | – | 3.8 | – | 11.5-(−6) | – |
|
| – | – | 3.2 | – | 4.3 | 1.7 |
|
| – | – | 2.9 | 1.7 | 16.1 | – |
| Intelectin | – | – | 2.5 | – | 12.6 | – |
| Mannose binding lectin 2 | – | – | – | 3.0 | 3.1–2.1 | – |
| Fucolectin 2 | – | – | – | – | 2.7 | – |
| Fucolectin 4 | – | – | – | – | 2.1 | 1.9 |
|
| ||||||
| Tubulin-related genes | – | 27.2 | – | – | 2.0 | – |
| Myosin-related genes | – | 5.9 | 7.6–2.6 | 6–1.6 | 8.2–2.2 | – |
| – | – | 4.9–2.7 | – | – | – | |
| Actin-related genes | – | 3.1 | 3.4 | 7–1.5 | 4.7–2 | 1.8 |
| Coronin-1a | – | – | 2.9 | – | – | – |
|
| ||||||
|
| ||||||
|
| – | – | – | – | 3.3 | – |
|
| – | – | – | – | 3.3 | – |
| Autophagy | ||||||
|
| – | – | 6.8 | – | 9.9 | – |
| Calpain | – | – | – | −3.9 | −4.7 | – |
| p53 apoptosis effector related to PMP-22 | – | – | – | – | 33.5 | – |
| Apoptosis-inducing factor 3 | – | – | – | – | 6.8 | – |
|
| – | – | – | – | 3.0 | – |
|
| – | 4.8 | ||||
|
| ||||||
|
| ||||||
|
| 2.2 | 8.5–5.2 | – | – | – | – |
| src-family tyrosine kinase SCK | – | 17.2 | – | – | – | – |
|
| – | 5.4 | – | – | – | – |
|
| – | 5.1 | – | – | – | – |
|
| – | 3.7 | – | 16.9 | – | – |
|
| – | 3.5 | – | 11.1 | – | – |
|
| – | – | 8.6 | – | 25.3 | – |
|
| – | – | 4.9 | – | 4.3 | – |
|
| – | – | 4.5 | 4.2 | 4.0 | – |
|
| – | – | 4.5 | – | 4.2 | – |
|
| – | – | 3.3 | – | 6.9 | – |
|
| – | – | 3.1 | – | 6.9 | – |
|
| – | – | −2.0 | −2.0 | – | – |
|
| – | – | −2.4 | – | – | – |
|
| – | – | −2.4 | – | – | – |
|
| – | – | −1.9 | −2.0 | – | – |
| NF-Κβ inhibitor alpha | – | – | – | 3.3 | −4.8 | – |
|
| – | – | – | 2.8 | 3.6 | – |
|
| – | – | – | 2.2 | – | – |
|
| – | – | – | −2.3 | – | – |
| c-myc binding protein | – | – | – | −5.5 | – | – |
|
| – | – | – | – | 24.3 | – |
| NF-Κβ p105 subunit | – | – | – | – | 4.8 | – |
| Kdel receptor 3 | – | – | – | – | 4.3 | – |
|
| – | – | – | – | 4.0 | – |
|
| – | – | – | – | 3.5 | 3.1 |
| – | – | – | – | 2.6 | – | |
|
| – | – | – | – | 2.1 | – |
|
| ||||||
| Interferon induced protein 2 | – | 20.1 | – | – | – | – |
|
| – | 17.2 | – | – | 3.5 | 27.8 |
| Granulin | – | 9.3 | – | – | – | – |
| IL8 precursor | – | 7.5 | – | – | – | – |
| IL1β receptor type 1 soluble | – | 5.5 | – | – | −4.2 | – |
| Progranulin type 1 | – | 5.5 | – | – | – | – |
| IL1 receptor type 1 | – | 4.4 | – | – | −6.2 | – |
|
| – | – | 8.5 | – | 14.8 | – |
| IL10 receptor β | – | – | 4.9 | – | 22.2 | – |
|
| – | – | 4.4 | – | – | – |
|
| – | – | 2.7 | – | 6.0 | – |
|
| – | – | 2.4 | – | – | – |
| nuclear factor interleukin 3-regulated protein | – | – | – | 10.1 | 3.5 | – |
| IL6 receptor subunit β precursor | – | – | – | 6.8 | 4.3 | 2.4 |
|
| – | – | – | 2.7 | – | – |
|
| – | – | – | 2.2 | – | – |
| IRF2, promoter region | – | – | – | 2.2 | – | – |
| Tumor necrosis factor receptor ( | – | – | – | – | 15.9 | – |
| TNF receptor member 27 | – | – | – | – | 6.0 | – |
|
| – | – | – | – | 3.3–2.8 | – |
| IL1 receptor-like | – | – | – | – | 3.1 | – |
|
| – | – | – | – | 2.6 | – |
| Allograft inflammatory factor-1 | – | – | – | – | 2.6 | – |
| TNF receptor associated factor 2 | – | – | – | – | 2.4 | – |
|
| – | – | – | – | 2.1 | – |
|
| – | – | – | – | – | 2.2 |
|
| ||||||
| CC CK3 | – | 3.6 | – | – | – | – |
| C-C receptor type 4 | – | – | 6.2 | – | – | – |
| CK 21 precursor | – | – | 4.1 | – | – | – |
| CCL4 | – | – | – | – | 8.6 | 13.4 |
| CK 4 precursor | – | – | – | – | 8.2 | – |
| CK 19 precursor | – | – | – | – | 5.2 | – |
| CK 10 precursor | – | – | – | – | 2.2 | – |
|
| ||||||
| Ciclooxigenase-2 ( | 5.5 | 32.1 | – | – | – | – |
| Hyaluronidase-2 ( | 2.5 | 26.6 | – | – | – | – |
| – | 61.5–40 | – | – | – | – | |
| Leukotriene | – | 5.2 | – | – | – | – |
| Prostaglandin | – | 11.0 | – | – | – | – |
|
| ||||||
| Coagulation factor VIII | – | 22.4–9.1 | – | – | – | – |
| Platelet receptor Gi24 | – | 2.0 | – | – | – | – |
| Antithrombin protein | – | – | 3.8 | – | 4.1 | – |
| Thrombin protein | – | – | 3.4 | – | – | – |
| Thrombospondin | – | – | – | – | 7.1–3 | – |
| Coagulation factor V | – | – | – | – | 4.6 | – |
| Fibrinogen | – | – | – | – | 4.0 | – |
| Angiotensinogen | – | – | – | – | 3.3 | – |
| Plasminogen | – | – | – | – | 2.0 | 1.9 |
| Multiple coagulation factor | – | – | – | – | – | 3.1 |
|
| ||||||
|
| – | 5.9 | – | – | −3.7 | – |
|
| – | – | 5.6 | – | 7.4 | – |
|
| – | – | 3.2 | – | 11.6 | – |
|
| – | – | 3.2 | – | 7.2 | – |
|
| – | – | – | – | 15.4 | – |
|
| – | – | – | – | 4.1 | – |
|
| – | – | – | – | 3.0 | – |
|
| ||||||
| Histone H2B | – | −2.3 | – | – | – | – |
| Histone H2AFX | – | – | 3.2 | 2.2 | – | – |
| Anti-silencing protein | – | – | 2.3 | – | 3.1 | – |
| Histone acetyltransferase type B catalytic subunit | – | – | 2.2 | – | 2.6 | – |
| Histone deacetylase 3 | – | – | 2.2 | – | – | – |
| Histone gene cluster XlH3-A ( | – | – | −1.4 | – | – | – |
| Histone acetyltransferase MYST2 | – | – | −1.4 | – | – | – |
| Histone H1x | – | – | −3.5 | – | – | – |
| Histone H3.3 | – | – | – | 1.3 | – | – |
| euchromatic histone-lysine N-methyltransferase 1b ( | – | – | – | −1.7 | – | – |
| Histone acetyltransferase MYST4 | – | – | – | −2.7 | – | – |
| Histone deacetylase 1 | – | – | – | −2.7 | – | – |
| Histone H2A.Z | – | – | – | −4.0 | – | – |
| Histone deacetylase 2 | – | – | – | −4.3 | – | – |
| Histone H1 | – | – | – | – | 7.4–5.9 | – |
| Histone H2AV | – | – | – | – | −1.8 | −1.6 |
|
| ||||||
|
| – | – | 2.5 | – | 4.4 | – |
|
| ||||||
| Systemic RNA deficient-1 ( | – | 10.5 | – | – | 5.4 | 2.2 |
|
| ||||||
| Hypoxia-inducible factor 1 alpha | – | 3.5 | – | – | – | – |
| Glutathione peroxidase | – | −2.1 | −1.5 | −1.7 | −2.0 | – |
| – | – | 3.6 | 5–1.8 | 36.9–8.2 | – | |
| Inositol hexakisphosphate ( | – | – | 2.0 | 2.9 | – | – |
|
| – | – | – | 31.7–2.2 | 25.2 | 9.1 |
| Osmotic stress gene | – | – | – | 6.7 | – | – |
List of selected differentially expressed genes (DEGs) from eels infected with V. vulnificus R99 strain. DEGs are grouped according to their putative biological function. The fold change (FC) values are based on the comparison between the time indicated on top of each column (3 hpi; 12 hpi) compared to time zero (0 hpi) for the same type of sample [B (blood), RBCs (red blood cells), or WBCs (white blood cells)]. FC value represents the mean obtained from 3 independent biological samples. –Not detected as differentially expressed.
Identified DEGs are indicated.
FC: fold change value for each individual gene. See .
Relevant mRNAs detected by RT-qPCR.
Figure 2Red blood cells (RBCs) and white blood cells (WBCs) elicit a different immune response against V. vulnificus. Venn diagram depicting the overlap of the differentially expressed genes (DEGs) between RBCs and WBCs at 3 hpi (A) and 12 hpi (B).
Proteolytic, hemolytic and bacteriolytic activity of eel serum before and after V. vulnificus infection.
| Serum sample | Proteolytic activity | Hemolytic activity | Bacteriolytic activity |
|---|---|---|---|
| Non-infected | – | 1:2 | 1:2 |
| 0 hpi | – | 1:8 | 1:4 |
| 3 hpi | 1:8 | 1:8 | 1:4 |
| 12 hpi | 1:4 | 1:4 | 1:8 |
Eels were infected by immersion and the lytic activities were determined in serum from non-infected eels (control), and eels infected at different hours post infection (hpi). Results are presented as the titter (maximal dilution of serum with a positive result in 3 independent biological samples) of the corresponding activity. –Without activity.
Proteolytic activity: evaluated by plating 5 μl of the serum samples and dilutions (serial dilution 1:2 to 1:64 on PBS) on 1% agarose plates supplemented with 5% casein. The maximal serum dilution that produced a transparent halo was considered as the titter of this activity.
Hemolytic activity: evaluated by plating 5 μl of the serum samples and dilutions (serial dilution 1:2 to 1:64 on PBS) on 1% agarose plates supplemented with 1% erythrocytes (bovine erythrocytes from Sigma). The maximal serum dilution that produced a transparent halo was considered as the titter of this activity.
Bacteriolytic activity: evaluated by plating 5 μl of the serum samples and dilutions (serial dilution 1:2 to 1:64 on PBS) on LB-1 plates inoculated with a V. vulnificus lawn. The maximal serum dilution that inhibited bacterial growth was considered as the titter of this activity.
Early diagnosis of fish vibriosis due to V. vulnificus by RT-qPCR.
| Gene name | Gene acronym | 3 hpi | 12 hpi |
|---|---|---|---|
| Nephrosin |
| 4.2 (+) | 1.5 (=) |
| Cyclooxygenase 2 |
| 21.9 (++) | 10.5 (++) |
| Matrix metalloproteinase-9 |
| 3.1 (+) | 2.9 (+) |
| Systemic RNAi deficient-1 |
| 11.31 (++) | 2.5 (+) |
Blood samples taken at 3 and 12 hpi from infected and control animals were used to determine the expression of genes selected as septicemic markers by RT-qPCR. Results were obtained using act as the reference gene and the fold induction (2-ΔΔCt) for each gene was calculated. Primers used are listed in Supplementary Table S1. Fold induction values qualitative classification: =, −2 < X < 2; +, 2 ≤ X < 10; ++, 10 ≤ X < 25.
Figure 3Model of the immune response in eel blood against V. vulnificus infection: early phase of vibriosis (3 hpi). The model shows the resultant proteins produced by the main transcripts differentially expressed by eels’ blood cells during the early phase of Vv-vibriosis (at 3 hpi with V. vulnificus R99 strain) infection. The putative translated proteins from the major immune-related pathways are represented in a code color depending on the gene modulation: upregulated (red) and downregulated (green).
Figure 4Model of the immune response in eel blood against V. vulnificus infection: late phase of vibriosis (12 hpi). The model shows the resultant proteins produced by the main transcripts differentially expressed by eels’ blood cells during the late phase of Vv-vibriosis (at 12 hpi with V. vulnificus R99 strain) infection. The putative translated proteins from the major immune-related pathways are represented in a code color depending on the gene modulation: upregulated (red) and downregulated (green).